安体维康联合拉米夫定治疗乙肝病毒感染的临床研究  

CLINICAL STUDY ON TREATING CHRONIC HEPATITIS B VIRUS INFECTION WITH ANTIVIRUS COMPOUND AND LAMIVUDINE

作　　者：徐向田[1] 马建民[1] 李玉兰 郝丽梅 

机构地区：[1]临沂医学专科学校,山东临沂276002 [2]临沂市肝胆病医院

出　　处：《临沂医学专科学校学报》2004年第6期405-407,共3页Journal of Linyi Medical College

基　　金：国家科技部创新基金项目;编号 :0 1C2 62 13 70 0 15 5

摘　　要：目的　 探讨安体维康和拉米夫定联用治疗乙型肝炎病毒 (HBV)感染的临床疗效。方法　选择慢性HBV感染患者 10 5例。其中 4 6例慢性HBV携带者 ,随机分为治疗组 2 5例 ,对照组 2 1例 ;5 9例慢性乙型肝炎 ,随机分为治疗组 32例 ,对照组 2 7例。治疗组均给予安体维康和拉米夫定口服 ,对照组给予灵芝气血宝口服。两组肝功能异常者均加用凯西莱、肝力宝等进行保肝治疗。结果　口服拉米夫定和安体维康 3个月时 ,血清中HBeAg和HBVDNA转阴率 ,慢性HBV携带者分别为 2 4 %和 76 % ,与对照组相比差异显著 (P <0 .0 5 ) ;慢性乙型肝炎分别为 4 6 .88%和 81.2 5 % ,与对照组相比差异显著 (P <0 .0 5 )。结论　 安体维康和拉米夫定联用能明显提高HBeAg和HBVDNA的转阴率 ,疗效明显。Objective To explore the clinical effects of treating chronic Hepatitis B virus(HBV) infection with antivirus compound (ATVC) and lamivudine (LAM).Methods 105 cases of chronic HBV infection(46 cases of chronic HBV carrier,59 cases of chronic Hepatitis B),46 cases of chronic HBV carrier was divided into treatment group of 25 cases and control group of 21 cases.59 cases of chronic hepatitis B were divided into the treatment group(32 cases) and the control group(27cases).The virus resisting medicines (LAM and ATVC) were applied to the treatment groups for 3 months.ResultsAfter 3 months of treatment,the HBeAg and HBVDNA negative conversion rates in the blood of the chronic hepatitis B carrier group were 24% and 76% respectively.The chronic hepatitis B negative conversion rates in the treatment group were 46.88% and 81.25%,Th negative conversion the two groups rate were higher than that of control group (P<0.05)。Conclusion ATVC and LAM can effectively improve the negative conversion rate of HBVDNA and HBeAg.

关 键 词：安体维康 拉米夫定 乙型肝炎病毒 

分 类 号：R944.5[医药卫生—药剂学]